Cellectar BioSciences FY26 Q2 net loss widens to about $12.6 million; R&D expense rises 91% to about $4.56 million vs FY25 Q2

• Cellectar BioSciences posted a net loss of about $12.6 million for the six months ended June 30, 2026.
• Research and development expense rose 30% to about $7.57 million, driven by higher clinical and manufacturing costs tied to confirmatory and TNBC studies.
• General and administrative expense fell 18% to about $5.43 million on lower professional fees, pre-commercialization spend, and personnel costs.
• Cash totaled about $34 million at June 30, 2026; management said liquidity could run out beyond the second quarter of 2027 without added capital.
• Phase 3 confirmatory work in Waldenstrom macroglobulinemia began in June 2026; a May financing provided about $35 million upfront with up to $105 million milestone-based.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-095426), on August 13, 2026, and is solely responsible for the information contained therein.